These molecular subtypes are sensible to endocrine therapy, thus the ER blocker Tamoxifen, is considered the first-line hormonal treatment for estrogen receptor positive (ER+) breast cancer[97,98]. The gene discussed is ESR1; the disease is breast cancer.